Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-01-04 Sale(A) |
2025-01-24 4:15 pm |
Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER |
40,000 | $45.29 | $1,811,600 | 0 (Direct) |
View |
| 2023-11-04 Sale |
2024-01-08 4:43 pm |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $45.29 | $1,811,600 | 53,622 (Direct) |
View |
| 2023-06-08 Sale |
2023-06-12 4:13 pm |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $46.61 | $1,864,239 | 207,244 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-18 Option Award |
2025-02-19 4:15 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER |
44,000 | $0 | 44,000 (Direct) |
View |
| 2024-01-04 Exercise(A) |
2025-01-24 4:15 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER |
40,000 | $16 | 0 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:40 pm |
N/A 2034-02-12 |
Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-01-04 Exercise |
2024-01-08 4:43 pm |
N/A 2030-04-06 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $0 | 53,622 (Direct) |
View |
| 2023-11-04 Exercise |
2024-01-08 4:43 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $16 | 53,622 (Direct) |
View |
| 2023-06-08 Exercise |
2023-06-12 4:13 pm |
N/A 2030-04-06 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $0 | 207,244 (Direct) |
View |
| 2023-06-08 Exercise |
2023-06-12 4:13 pm |
N/A N/A |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $16 | 207,244 (Direct) |
View |
| 2023-02-16 Option Award |
2023-02-17 4:14 pm |
N/A 2033-02-15 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 4:15 pm |
N/A 2032-01-20 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
50,000 | $0 | 50,000 (Direct) |
View |
| 2021-01-10 Option Award |
2021-01-12 5:25 pm |
N/A 2031-01-09 |
Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer |
49,150 | $0 | 49,150 (Direct) |
View |